NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
VERAXA Biotech Pipeline and Partnering Update FAQ
VERAXA Biotech (NASDAQ: VRXA) provided a corporate update highlighting progress on its proprietary BiTAC platform for T-cell engagers and bispecific ADCs targeting solid tumors, with plans to advance lead candidate VXA-102 to IND/CTA readiness by early 2028 while seeking partnerships for non-BiTAC programs.
VERAXA's pipeline is centered on its proprietary BiTAC platform, which includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
VERAXA reported continued advancement of its BiTAC platform and growing interest from potential pharmaceutical partners, as well as plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs.
VERAXA aims to advance its lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.
The company cites strong industry interest in T-cell engager and ADC technologies, and recent partnering discussions at conferences like BIO International reinforced confidence that its BiTAC platform is differentiated and can secure strategic collaborations.
VERAXA plans to monetize selected non-BiTAC programs to help finance future development, while prioritizing investment in its BiTAC portfolio.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned life science research institution.
The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH, indicating the proprietary nature of their bispecific T-cell engager platform.